101-32-6

Usage

Uses

Used in Organic Synthesis:
2,2'-(Benzylimino)diethanol is used as a versatile building block for the synthesis of complex organic molecules. Its presence of both the benzyl group and the hydroxyethyl moiety allows for a wide range of chemical reactions, making it a valuable component in the creation of pharmaceutical intermediates and compounds for drug discovery and development.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,2'-(Benzylimino)diethanol is used as a key intermediate in the synthesis of various drug candidates. Its unique structure contributes to the development of compounds with specific pharmacological or biological activities, highlighting its significance in medicinal chemistry and the synthesis of bioactive substances.
Used in Drug Discovery and Development:
2,2'-(Benzylimino)diethanol is employed as a crucial component in drug discovery and development processes. Its chemical versatility enables the design and synthesis of novel compounds with potential therapeutic applications, further emphasizing its importance in the advancement of new medications and treatments.

InChI:InChI=1/C11H17NO2/c13-8-6-12(7-9-14)10-11-4-2-1-3-5-11/h1-5,13-14H,6-10H2

Upstream product

• 75-21-8 oxirane 
• 100-46-9 benzylamine 
• 100-44-7 benzyl chloride 
• 111-42-2 2,2'-iminobis[ethanol] 
• 100-39-0 benzyl bromide 
• 5453-99-6 4-benzyl-morpholin-2-one 
• 1024-41-5 benzyl tosylate 
• 540-51-2 2-bromoethanol 
• 104-63-2 N-Benzylethanolamine 
• 95-78-3 2,5-Dimethylaniline 
• 17136-37-7 benzyliminodiacetic acid diethyl ester 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 
• 113618-73-8 2-[benzyl-(2-benzyloxy-ethyl)-amino]-ethanol 
• 102542-05-2 benzyl-bis-[2-(2-diethylamino-ethoxy)-ethyl]-amine 
• 62538-57-2 4-benzyl-1,7,12,15-tetraoxa-4-aza-cyclononadecane-8,11,16,19-tetraone 
• 15831-62-6 N-benzyl-diethanolamine N-oxide 
• 98529-01-2 6-benzyl-2-phenyl-[1,3,6,2]dioxazaborocane 
• 23538-88-7 N-benzyl-N,N-bis(2-phthalimidoethyl)amine 
• 71089-11-7 1-benzyl-1-aza-15-crown-5 
• 107102-14-7 2,3-benzo-10-benzyl-10-aza-1,4,7,13-tetraoxa-2-cyclopentadecene 
• 10429-82-0 N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine hydrochloride 
• 205248-61-9 C₂₃H₃₉NO₇ 
• 205248-60-8 N-benzyl monoaza-21-crown-7 
• 922527-86-4 N-benzyl monoaza-27-crown-9 
• 204580-55-2 N-benzyl-2,2'-bis(tert-butyldimethylsilyloxy)diethylamine 

Relevant academic research and scientific papers

Substitution effect, absorption, and fluorescence behaviors of 11,12-benzo-1,7,10,13-tetraoxa-4-azacyclopentadec-11-ene (Benzoaza-15-crown-5) derivatives upon cation complexation in solvent extraction

Substitution effect, absorption, and fluorescence behaviors of some benzoaza-15-crown-5 derivatives upon cation complexation in solvent extraction were studied. The introduction of a substituent on the nitrogen atom in benzoaza-15-crown-5 enhanced extractabilities in the solvent extraction of aqueous alkali metal picrates. The nondonating substituents raised the cation selectivity for Na+ over K+, but the donating substituents reduced the cation selectivity. The absorption and fluorescence spectral behavior was different with the alkali metal cations.

Complex Formation between Boric Acid and Triethanolamine in Aqueous Solutions

The complex formation behavior between boric acid and triethanolamine (TEA, H3L) in aqueous solutions was thoroughly examined by 11BNMR spectroscopy. In chloroform, one 11BNMR signal appeared due to triethanolamine borate (TEA-B, L-B) at -4.6 ppm, whereas in aqueous solutions two signals appeared due to TEA-B and a new boron complex at -5.8 and -9.5 ppm, respectively, in addition to a signal ascribed to boric acid and borate ion. The area ratios between the signals at -5.8 and -9.5 ppm were almost constant regardless of the molar ratios between boric acid and TEA, suggesting that the new complex is a 1: 1 complex between boric acid and TEA. Both complexes were stable in aqueous solutions over the pH range of 6.7 to 10.9. Their chemical shift values were constant and independent of the pH value. This also implies that the new complex has a tetrahedral structure around the boron atom, similar to TEA-B. Based on 1H and 13C NMR spectroscopy and a preliminary examination of complexation between boric acid and aminoalkanols, we have concluded that the new complex (NB, HL-B(OH)) is a 1 : 1 boron to TEA complex with a bicyclo[3,3,0]structure having a boron-nitrogen bond.

Synthesis and antidepressant activity of optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol (SIPI5056)

Four optical isomers of SIPI5056 were synthesized and evaluated for their antidepressant activities and acute toxicities as novel multiple reuptake inhibitors of monoamine transmitters. Chiral alanines were used as educts to prepare their respective target compounds in nine steps. Pharmacological results showed that the (1R,2S)-SIPI5056 isomer has higher inhibitory activity and lower toxicity than other three isomers and is worthy of further development.

A mild and efficient cyanosilylation of ketones using in situ generated n-oxides-ti(iPrO)4 complexes as catalysts

The addition of TMSCN to ketones catalyzed by complex of racemic N-(2′-pyridylmethyl)-2-diphenylhydroxymethylpyrrolidine N-oxide (rac-1) or N-benzyl-N,N-dihydroxyethylamine N-oxide and Ti(iPrO)4 affords the racemic O-TMS cyanohydrins in good to excellent isolated yields (up to 97%) under mild reaction conditions.

Aza-crown ether complex cation ionic liquids: Preparation and applications in organic reactions

Aza-crown ether complex cation ionic liquids (aCECILs) were devised, fabricated, and characterized by using NMR spectroscopy, MS, thermogravimetric differential thermal analysis (TG-DTA), elemental analysis and physical properties. These new and room-temperature ILs were utilized as catalysts in various organic reactions, such as the cycloaddition reaction of CO2 to epoxides, esterification of acetic acid and alcohols, the condensation reaction of aniline and propylene carbonate, and Friedel-Crafts alkylation of indole with aldehydes were investigated carefully. In these reactions, the ionic liquid exhibited cooperative catalytic activity between the anion and cation. In addition, the aza-[18-C-6HK][HSO4]2 was the best acidic catalyst in the reactions of esterification and Friedel-Crafts alkylation under mild reaction conditions. Jewel in the crown: Nine new and room-temperature aza-crown ether complex ionic liquids (aCECILs) composed of multiple cations and anions were fabricated through a convenient procedure (see scheme). Some of them were used as catalysts in various organic reactions, such as the cycloaddition reaction of CO2 to propylene oxide, esterification of acetic acid and alcohols, the condensation of aniline and propylene carbonate, and Friedel-Crafts alkylation of indole with aldehydes.

Steroidal Lariat Ethers: A New Class of Macrocycles and the Crystal Structure of N-(Cholesteryloxycarbonyl)aza-15-crown-5

Several examples of a new class of lariat ethers, those having steroidal side arms, are reported.These include the following carbon-pivot and nitrogen-pivot structures: 2-(3-dihydrocholesteryloxymethyl)-15-crown-5, mp 61-63 deg C; N-(3-cholesteryloxycarbonylmethyl)aza-15-crown-5, mp 85-86 deg C; N-(3-cholesteryloxycarbonylmethyl)aza-18-crown-6, mp 66-67 deg C; N-(3-dihydrocholesteryloxycarbonylmethyl)aza-15-crown-5, mp 60-61 deg C; N-(3-dihydrocholesteryloxycarbonylmethyl)aza-18-crown-6, mp 55-56 deg C; N-(3-cholesteryloxycarbonyl)aza-15-crown-5, mp 96-98 dec C; and N-(3-cholesteryloxycarbonyl)aza-18-crown-6, mp 82-84 deg C.Alkali-metal cation binding by these structures is generally weak, since the macroring binding is not augmented by side arm donor group participation.The high lipophilicity of the side arm does not enhance the caion binding strength.The X-ray crystal structure of one of these novel lariat ethers, N-(cholesteryloxycarbonyl)aza-15-crown-5 has been determined.This is the first example of an uncomplexed, 15-membered crown ether compound containing only nitrogen and oxygen heteroatoms.The macroring structure has one N-C-C-O torsion angle anti; thus one methylene group is turned inward

Compound serving as SHP2 inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a compound serving as an SHP2 inhibitor and an application of the compound, and particularly provides a compound shown in a formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug of the compound, processes for the preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of SHP2 mediated diseases.

SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF

Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

Preparation method of 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride

The invention relates to the technical field of organic synthesis, in particular to a preparation method of 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride. The preparation method disclosed by the invention comprises the following steps of: (1) preparing benzyl diethanolamine by taking benzyl chloride and diethanolamine as raw materials; (2) preparing benzyl dichloroethylamine hydrochloride by taking benzyl diethanolamine and thionyl chloride as raw materials; and (3) preparing the 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride by taking the benzyl dichloroethylamine hydrochloride and the benzyl cyanide as raw materials. The preparation method disclosed by the invention is simple in process and suitable for industrial production, the HPLC content of the finally obtained 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride is greater than or equal to 98.0%, the total yield (based on diethanolamine) is greater than or equal to 89%, and the 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride has a very good market prospect.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).